Rashid, Md Mamunur Lee, Hyunbeom Park, Jinyoung Jung, Byung Hwa 2024-01-19T13:32:21Z 2024-01-19T13:32:21Z 2021-10-21 2021-11 0269-3879 https://pubs.kist.re.kr/handle/201004/116234 Mammalian or mechanistic target of rapamycin (mTOR) drives its fundamental cellular functions through two distinct catalytic subunits, mTORC1 and mTORC2, and is frequently dysregulated in most cancers. To treat cancers, developed mTOR inhibitors have been classified into first and second generations based on their ability to inhibit single (first-generation) and dual (second-generation) mTOR subunits. However, the underlying metabolic differences due to the effects of first- and second-generation mTOR inhibitors have not been clearly evaluated. In this study, rapamycin (sirolimus) and AZD8055 and PP242 were selected as first- and second-generation mTOR inhibitors, respectively, to evaluate the metabolic differences due to these two generations of mTOR inhibitors after a single oral dose using untargeted metabolomics and lipidomics approaches. The metabolic differences at each time point were compared using multivariate analysis. The multivariate and data analyses showed that metabolic disparity was more prominent within 8 h after drug administration and a broad class of metabolites were affected by the administration of both generations of mTOR inhibitors. Among the metabolite classes, changes in the pattern of fatty acids and glycerophospholipids were opposite, specifically at 4 and 8 h between the two generations of mTOR inhibitors. We speculate that the inhibition of the mTORC2 subunit by the second-generation mTOR inhibitor may have resulted in a distinct metabolic pattern between the first- and second-generation inhibitors. Finally, the findings of this study could assist in a more detailed understanding of the key metabolic differences caused by first- and second-generation mTOR inhibitors. English WILEY PERFORMANCE LIQUID-CHROMATOGRAPHY FATTY-ACID-METABOLISM MTOR IDENTIFICATION AZD8055 CANCER Comparative metabolomics and lipidomics study to evaluate the metabolic differences between first- and second-generation mammalian or mechanistic target of rapamycin inhibitors Article 10.1002/bmc.5190 1 BIOMEDICAL CHROMATOGRAPHY, v.35, no.11 BIOMEDICAL CHROMATOGRAPHY 35 11 scie scopus 000664774800001 2-s2.0-85108317748 Biochemical Research Methods Biochemistry & Molecular Biology Chemistry, Analytical Pharmacology & Pharmacy Biochemistry & Molecular Biology Chemistry Pharmacology & Pharmacy Article PERFORMANCE LIQUID-CHROMATOGRAPHY FATTY-ACID-METABOLISM MTOR IDENTIFICATION AZD8055 CANCER lipidomics mammalian or mechanistic target of rapamycin metabolomics mTOR inhibitor UHPLC-Orbitrap-MS